Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol 2021; 27(13): 1267-1282 [PMID: 33833481 DOI: 10.3748/wjg.v27.i13.1267]
Corresponding Author of This Article
Joseph M Pappachan, FRCP, MD, Consultant Physician-Scientist, Honorary Research Fellow, Senior Researcher, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 7, 2021; 27(13): 1267-1282 Published online Apr 7, 2021. doi: 10.3748/wjg.v27.i13.1267
Metabolic complications of hepatitis C virus infection
Rahul Chaudhari, Sherouk Fouda, Ashik Sainu, Joseph M Pappachan
Rahul Chaudhari, Department of Medicine, Pennsylvania Hospital of the University of Pennsylvania, Pennsylvania, PA 19104, United States
Sherouk Fouda, School of Health and Biomedical Sciences, RMIT University, Melbourne VIC 3000, Australia
Ashik Sainu, Department of Gastroenterology and Hepatology, Aster Oman Hospital, Al Ghubra, Muscat OM 133, Oman
Joseph M Pappachan, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom
Joseph M Pappachan, Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom
Joseph M Pappachan, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom
Author contributions: Chaudhari R and Fouda S performed extensive literature review and drafted the manuscript and share the first authorship jointly; Sainu A added points especially the hepatologic side of the work with additional literature review and revision; Pappachan JM conceived the idea, inputted additional scientific points especially the metabolic aspects, revised the entire work critically, and approved the final version for publication.
Conflict-of-interest statement: Dr. Pappachan and co-authors of this paper have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Joseph M Pappachan, FRCP, MD, Consultant Physician-Scientist, Honorary Research Fellow, Senior Researcher, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Received: January 23, 2021 Peer-review started: January 23, 2021 First decision: February 10, 2021 Revised: February 10, 2021 Accepted: March 12, 2021 Article in press: March 12, 2021 Published online: April 7, 2021 Processing time: 65 Days and 17.5 Hours
Core Tip
Core Tip: Available evidence proves a strong association between hepatitis C virus (HCV) and metabolic complications such as hyperlipidemia, hepatic steatosis, insulin resistance, metabolic syndrome, and diabetes mellitus. De novo development of insulin resistance and hepatic steatosis in chronic HCV infection influences the disease progression in the liver and enhances overall morbidity and mortality. The influence of metabolic diseases on HCV infection can increase disease severity. The interplay between HCV major proteins and the liver-muscle-adipose axis is complex and still not fully elucidated. Coexistence of metabolic diseases such as diabetes mellitus and HCV infection are also known to result in adverse outcomes of both disorders. There is evidence that successful treatment halts the progression of liver disease, but more studies are required on how treatment influences the metabolic manifestations.
